Developer docs
API playgroundTry for free, no card

Search company profiles

3Helix

Full company profile

uuid000b64p

Namestring
3Helix
Legal namestring
3Helix, Inc.
Websiteurl
3helix.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

3Helix, Inc. is a private life science tools and therapeutics company founded in 2015 and headquartered in Salt Lake City, Utah. The company develops and commercializes Collagen Hybridizing Peptides (CHPs) — short (30-amino-acid) synthetic peptides that selectively bind unfolded, damaged, or remodeling collagen by reforming the triple-helical structure. Because CHPs target the conserved Gly-X-Y repeating sequence common to all collagen types and species, they enable specific detection of tissue damage that traditional stains such as Masson's Trichrome or Picrosirius Red cannot differentiate from intact collagen. The current product portfolio comprises five labeled variants (F-CHP, B-CHP, R-CHP, In Vivo CHP, and Auto-CHP) sold as research reagents at unit prices of approximately $218-$429 per vial.

The company sells primarily to academic research institutions and pharmaceutical/biotech R&D groups working on fibrosis, cancer metastasis, osteoarthritis, myocardial infarction, and developmental biology, with a secondary customer base of contract research organizations. Revenue is generated through direct e-commerce (3helix.com), US distributors including Fisher Scientific, Advanced BioMatrix, and Echelon, and an international distributor network spanning Europe, Asia, and Oceania. The company also maintains an active application-notes and case-study publishing program supported by 700+ peer-reviewed publications that cite CHP products.

Beyond research reagents, 3Helix is advancing two strategic adjacencies: (1) a next-generation bioACTIVE CHP platform that combines targeted collagen binding with therapeutic payload delivery, positioning the technology for drug development applications, and (2) a CHP-based cosmetic ingredient (NeoHelix™ Regenerate) co-developed with BASF and launched in April 2026, representing the company's first commercial move outside life science research. The company is founder-led (CEO Mike Kirkness, PhD) with a small (1-10 employee) team and is not publicly listed.

Short descriptiontext

3Helix develops Collagen Hybridizing Peptides (CHPs) — synthetic peptides that selectively bind damaged collagen — sold as research reagents to academic labs and pharmaceutical/biotech R&D groups studying fibrosis, cancer, cardiovascular disease, and tissue remodeling.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSalt Lake City, United States
HQ citystring
Salt Lake City
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
collagen hybridizing peptides, life science research reagents, histopathology imaging tools, collagen damage detection, fibrosis research reagents
Industry2 codes
PRIMARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Life Science Research Reagents
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Research Reagent Sales
TypeOne Time License
Description

3Helix generates revenue through direct sales of Collagen Hybridizing Peptide products to research institutions, pharmaceutical companies, and biotech firms. Products are sold in various conjugate formats (F-CHP, R-CHP, B-CHP, In Vivo CHP, Auto-CHP) at unit-based pricing. Revenue is primarily one-time transactional for research reagents, with no recurring subscription component for standard products.

3helix.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales
Pricing details4 tiers
1F-CHP (Fluorescein Conjugate) - Standard research reagent for histology and immunofluorescence
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$218.00 USD per 60μg unit. Also available in 300μg size and as negative control (60μg).

3helix.com
2B-CHP (Biotin Conjugate) - Flexible detection options for immunofluorescence and immunohistochemistry
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Starting at $218.00 USD per unit. Available in 60μg and 300μg sizes with negative control options.

3helix.com
3R-CHP (Cy3 Conjugate) - Red fluorescence for tissues with high green autofluorescence
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Available in 60μg and 300μg sizes.

3helix.com
4In Vivo CHP (sCy7.5 Conjugate) - Near-infrared for in vivo imaging
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$429.00 USD per Target-sCy7.5-CHP (1 vial, 3 doses). Also available as control peptide and in kit format (10 targeted + 3 control doses).

3helix.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

3Helix manufactures and sells Collagen Hybridizing Peptide (CHP) research reagents — short synthetic peptides that selectively bind denatured, damaged, or remodeling collagen via triple-helix reformation. The portfolio includes five labeled variants (F-CHP, B-CHP, R-CHP, In Vivo CHP, Auto-CHP) used by academic, pharmaceutical, and biotech researchers in histopathology, fibrosis, cancer, cardiovascular, and in vivo imaging studies. The company is also developing a bioACTIVE CHP platform that combines collagen-targeting with therapeutic payload delivery.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Detection of fibrotic disease progression up to two times sooner than traditional staining methods in MASH research
+2 more records
Product overview1 text field

3Helix is a life science tools and therapeutics company founded in 2015, headquartered in Salt Lake City, Utah. Its core product line is Collagen Hybridizing Peptides (CHPs) — short synthetic peptides that selectively bind unfolded, damaged, or remodeling collagen for applications in therapeutics, cosmetics, drug delivery systems, and life science research tools. The portfolio includes five labeled variants: F-CHP (5-FAM fluorescein conjugate), B-CHP (biotin conjugate), R-CHP (Cy3 red-fluorescence conjugate), In Vivo CHP (sCy7.5 near-infrared conjugate), and Auto-CHP (biotin conjugate for automated staining platforms). The company is also developing a next-generation bioACTIVE CHP platform that both targets damaged collagen and delivers therapeutic payloads, and announced a CHP-based cosmetic ingredient called NeoHelix™ Regenerate in partnership with BASF.

Product and service5 records
1F-CHP (5-FAM Conjugate)
CategoryLife Science Research Reagent
Description

Collagen Hybridizing Peptide labeled with fluorescein (5-FAM) for direct fluorescence detection of denatured collagen in immunofluorescence, cell imaging, and SDS-PAGE in-gel western applications. Molecular weight 2952.01 g/mol, 85% purity by HPLC; available in 60µg and 300µg vial sizes plus negative control.

2B-CHP (Biotin Conjugate)
CategoryLife Science Research Reagent
Description

Collagen Hybridizing Peptide labeled with biotin for avidin/streptavidin-mediated detection, offering flexible options including non-green fluorescence, HRP-enzyme methods, and TEM imaging with streptavidin-conjugated gold nanoparticles. Molecular weight 2762.01 g/mol; available in 60µg and 300µg sizes with negative control options.

3R-CHP (Cy3 Conjugate)
CategoryLife Science Research Reagent
Description

Collagen Hybridizing Peptide labeled with sulfo-Cyanine3 for direct fluorescence detection of denatured collagen. Recommended for tissues with high autofluorescence in the green spectrum or to avoid spectral overlap with other markers. Molecular weight 3191.44 g/mol, excitation 548 nm, emission 563 nm; available in 60µg and 300µg sizes.

4In Vivo CHP (sCy7.5 Conjugate)
CategoryLife Science Research Reagent
Description

Collagen Hybridizing Peptide labeled with sulfonated-cyanine 7.5 dye for near-infrared fluorescence (NIRF) in vivo imaging of collagen damage in living animals. Features a modified sequence that does not require pre-activation heating, enabling direct injection and signal lasting for days at target sites. Molecular weight 3703.1 g/mol, excitation 778 nm, emission 797 nm; sold per vial (3 doses) at $429 USD, with control peptide and kit (10 targeted + 3 control doses) formats.

5Auto-CHP (Biotin Conjugate for Automated Staining)
CategoryLife Science Research Reagent
Description

Collagen Hybridizing Peptide specifically formulated for automated staining platforms (Leica Bond-RXm, Roche Discovery Ultra, Biocare Medical Valent). The new sequence eliminates the pre-activation heating step and remains stable in solution at 4°C for months; biotin-labeled for flexible detection with immunofluorescence and immunohistochemistry workflows.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-10-01
Description

3Helix announced a partnership with BASF in fall 2023 to develop a CHP-based cosmetic ingredient. BASF subsequently launched NeoHelix™ Regenerate in April 2026, representing the first commercial application of 3Helix's collagen-targeting technology in the cosmetics sector. This partnership validates 3Helix's technology beyond research applications into commercial consumer products.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

The world's largest generalist life-science reagent supplier, offering collagen stains, antibodies, and biochemicals across every research category. Comparable as the dominant broad incumbent that supplies the same histology and collagen-research customers and could leverage scale to compete.

TypeEmerging player
Description

Clinical-stage biopharmaceutical company developing therapeutics for fibrosis and connective tissue disorders. Comparable as an emerging player targeting the same fibrotic-disease indications (IPF, MASH) that 3Helix's bioACTIVE CHP platform is positioned to address therapeutically.

TypeDirect peer
Description

Specialty reagent developer of fluorescent dyes, viability assays, and histology stains used in similar research workflows. Comparable as a similarly sized specialty reagent vendor selling fluorescent conjugates (analogous to 3Helix's F-CHP and R-CHP) into the same academic and pharma imaging markets.

4Nordic BioSite
TypeOthers
Description

Pan-European distributor of specialty life-science research reagents. Comparable as a channel peer that aggregates and distributes niche reagents (including collagen-related products) across European academic and biotech customers that 3Helix also serves via its regional distributor network.

TypeBroad incumbent
Description

Global antibody and reagent supplier with a deep catalog covering ECM, collagen, and fibrosis targets. Comparable as a broad incumbent serving the same research customer base with overlapping product categories and the distribution scale to challenge 3Helix's niche.

TypeBroad incumbent
Description

Leading antibody and reagent manufacturer for signal transduction, including fibrosis and ECM-related targets. Comparable as a broad incumbent supplying the same academic and pharma histology customers with collagen- and fibrosis-relevant research tools that could substitute for CHPs.

TypeBroad incumbent
Description

Major life-science tools company encompassing R&D Systems, Novus Biologicals, and Tocris, with extensive antibody and reagent catalogs covering histology, fibrosis, and ECM research. Comparable as a broad incumbent whose portfolio overlaps 3Helix's collagen/fibrosis research applications and which could credibly develop competing collagen-damage reagents.

TypeDirect peer
Description

Life science research reagent manufacturer focused on lipid signaling and related research tools, with a distribution footprint that overlaps 3Helix's US academic and pharma channels. Comparable as a similarly sized specialty reagent vendor targeting niche research applications.

TypeDirect peer
Description

Develops recombinant human collagen and bioengineered ECM products for research and medical applications. Comparable because it operates in the collagen-targeted regenerative and research market with overlapping customers in fibrosis and tissue-repair research.

10Advanced BioMatrix
TypeDirect peer
Description

Specializes in collagen-based, ECM, and 3D tissue research reagents, including collagen hydrogels and scaffolds. Directly comparable because it serves the same collagen-research customer base with overlapping histology and tissue-engineering products, and is also a US distributor for 3Helix's CHP products.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

3Helix

Life Science Research Reagents3helix.com

3Helix develops Collagen Hybridizing Peptides (CHPs) — synthetic peptides that selectively bind damaged collagen — sold as research reagents to academic labs and pharmaceutical/biotech R&D groups studying fibrosis, cancer, cardiovascular disease, and tissue remodeling.

What 3Helix does

3Helix, Inc. is a private life science tools and therapeutics company founded in 2015 and headquartered in Salt Lake City, Utah. The company develops and commercializes Collagen Hybridizing Peptides (CHPs) — short (30-amino-acid) synthetic peptides that selectively bind unfolded, damaged, or remodeling collagen by reforming the triple-helical structure. Because CHPs target the conserved Gly-X-Y repeating sequence common to all collagen types and species, they enable specific detection of tissue damage that traditional stains such as Masson's Trichrome or Picrosirius Red cannot differentiate from intact collagen. The current product portfolio comprises five labeled variants (F-CHP, B-CHP, R-CHP, In Vivo CHP, and Auto-CHP) sold as research reagents at unit prices of approximately $218-$429 per vial.

The company sells primarily to academic research institutions and pharmaceutical/biotech R&D groups working on fibrosis, cancer metastasis, osteoarthritis, myocardial infarction, and developmental biology, with a secondary customer base of contract research organizations. Revenue is generated through direct e-commerce (3helix.com), US distributors including Fisher Scientific, Advanced BioMatrix, and Echelon, and an international distributor network spanning Europe, Asia, and Oceania. The company also maintains an active application-notes and case-study publishing program supported by 700+ peer-reviewed publications that cite CHP products.

Beyond research reagents, 3Helix is advancing two strategic adjacencies: (1) a next-generation bioACTIVE CHP platform that combines targeted collagen binding with therapeutic payload delivery, positioning the technology for drug development applications, and (2) a CHP-based cosmetic ingredient (NeoHelix™ Regenerate) co-developed with BASF and launched in April 2026, representing the company's first commercial move outside life science research. The company is founder-led (CEO Mike Kirkness, PhD) with a small (1-10 employee) team and is not publicly listed.

3Helix firmographics

Firmographics
Name
3Helix
Legal name
3Helix, Inc.
Website
https://3helix.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
3Helix develops Collagen Hybridizing Peptides (CHPs) — synthetic peptides that selectively bind damaged collagen — sold as research reagents to academic labs and pharmaceutical/biotech R&D groups studying fibrosis, cancer, cardiovascular disease, and tissue remodeling.
Ownership category
akta.pro rank

3Helix industry classification

Industry
Product category
Life Science Research Reagents
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Collagen hybridizing peptides
  • Life science research reagents
  • Histopathology imaging tools
  • Collagen damage detection
  • Fibrosis research reagents

Where 3Helix is headquartered

Location

Headquarters

HQ city
Salt Lake City
HQ country
United States
HQ region
North America

Offices1 record

Markets served

3Helix business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales

Revenue model

  1. Research Reagent Sales: 3Helix generates revenue through direct sales of Collagen Hybridizing Peptide products to research institutions, pharmaceutical companies, and biotech firms. Products are sold in various conjugate formats (F-CHP, R-CHP, B-CHP, In Vivo CHP, Auto-CHP) at unit-based pricing. Revenue is primarily one-time transactional for research reagents, with no recurring subscription component for standard products.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goF-CHP (Fluorescein Conjugate) - Standard research reagent for histology and immunofluorescence
Unit PricingPay-as-you-goB-CHP (Biotin Conjugate) - Flexible detection options for immunofluorescence and immunohistochemistry
Unit PricingPay-as-you-goR-CHP (Cy3 Conjugate) - Red fluorescence for tissues with high green autofluorescence
Unit PricingPay-as-you-goIn Vivo CHP (sCy7.5 Conjugate) - Near-infrared for in vivo imaging

Go-to-market motion2 records

Distribution channels5 records

Marketing channels7 records

3Helix product offering

Product offering

Core offering

3Helix manufactures and sells Collagen Hybridizing Peptide (CHP) research reagents — short synthetic peptides that selectively bind denatured, damaged, or remodeling collagen via triple-helix reformation. The portfolio includes five labeled variants (F-CHP, B-CHP, R-CHP, In Vivo CHP, Auto-CHP) used by academic, pharmaceutical, and biotech researchers in histopathology, fibrosis, cancer, cardiovascular, and in vivo imaging studies. The company is also developing a bioACTIVE CHP platform that combines collagen-targeting with therapeutic payload delivery.

Product overview

3Helix is a life science tools and therapeutics company founded in 2015, headquartered in Salt Lake City, Utah. Its core product line is Collagen Hybridizing Peptides (CHPs) — short synthetic peptides that selectively bind unfolded, damaged, or remodeling collagen for applications in therapeutics, cosmetics, drug delivery systems, and life science research tools. The portfolio includes five labeled variants: F-CHP (5-FAM fluorescein conjugate), B-CHP (biotin conjugate), R-CHP (Cy3 red-fluorescence conjugate), In Vivo CHP (sCy7.5 near-infrared conjugate), and Auto-CHP (biotin conjugate for automated staining platforms). The company is also developing a next-generation bioACTIVE CHP platform that both targets damaged collagen and delivers therapeutic payloads, and announced a CHP-based cosmetic ingredient called NeoHelix™ Regenerate in partnership with BASF.

Differentiator

Problem solved

Functional benefit

Products and services

  • F-CHP (5-FAM Conjugate) Collagen Hybridizing Peptide labeled with fluorescein (5-FAM) for direct fluorescence detection of denatured collagen in immunofluorescence, cell imaging, and SDS-PAGE in-gel western applications. Molecular weight 2952.01 g/mol, 85% purity by HPLC; available in 60µg and 300µg vial sizes plus negative control.
  • B-CHP (Biotin Conjugate) Collagen Hybridizing Peptide labeled with biotin for avidin/streptavidin-mediated detection, offering flexible options including non-green fluorescence, HRP-enzyme methods, and TEM imaging with streptavidin-conjugated gold nanoparticles. Molecular weight 2762.01 g/mol; available in 60µg and 300µg sizes with negative control options.
  • R-CHP (Cy3 Conjugate) Collagen Hybridizing Peptide labeled with sulfo-Cyanine3 for direct fluorescence detection of denatured collagen. Recommended for tissues with high autofluorescence in the green spectrum or to avoid spectral overlap with other markers. Molecular weight 3191.44 g/mol, excitation 548 nm, emission 563 nm; available in 60µg and 300µg sizes.
  • In Vivo CHP (sCy7.5 Conjugate) Collagen Hybridizing Peptide labeled with sulfonated-cyanine 7.5 dye for near-infrared fluorescence (NIRF) in vivo imaging of collagen damage in living animals. Features a modified sequence that does not require pre-activation heating, enabling direct injection and signal lasting for days at target sites. Molecular weight 3703.1 g/mol, excitation 778 nm, emission 797 nm; sold per vial (3 doses) at $429 USD, with control peptide and kit (10 targeted + 3 control doses) formats.
  • Auto-CHP (Biotin Conjugate for Automated Staining) Collagen Hybridizing Peptide specifically formulated for automated staining platforms (Leica Bond-RXm, Roche Discovery Ultra, Biocare Medical Valent). The new sequence eliminates the pre-activation heating step and remains stable in solution at 4°C for months; biotin-labeled for flexible detection with immunofluorescence and immunohistochemistry workflows.

Quantifiable outcome

  • Detection of fibrotic disease progression up to two times sooner than traditional staining methods in MASH research
  • +2 more outcomes

Companies that use 3Helix

Customer profile

Segments3 records

Ideal customer profiles3 records

3Helix technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

3Helix partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • BASFcoreStrategic or Co-development Partner · 1 October 20233Helix announced a partnership with BASF in fall 2023 to develop a CHP-based cosmetic ingredient. BASF subsequently launched NeoHelix™ Regenerate in April 2026, representing the first commercial application of 3Helix's collagen-targeting technology in the cosmetics sector. This partnership validates 3Helix's technology beyond research applications into commercial consumer products.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

3Helix competitors and assessment

Company assessment

Broad incumbents

  • Sigma-Aldrich (Merck KGaA Life Science): The world's largest generalist life-science reagent supplier, offering collagen stains, antibodies, and biochemicals across every research category. Comparable as the dominant broad incumbent that supplies the same histology and collagen-research customers and could leverage scale to compete.
  • Abcam (Danaher): Global antibody and reagent supplier with a deep catalog covering ECM, collagen, and fibrosis targets. Comparable as a broad incumbent serving the same research customer base with overlapping product categories and the distribution scale to challenge 3Helix's niche.
  • Cell Signaling Technology: Leading antibody and reagent manufacturer for signal transduction, including fibrosis and ECM-related targets. Comparable as a broad incumbent supplying the same academic and pharma histology customers with collagen- and fibrosis-relevant research tools that could substitute for CHPs.
  • Bio-Techne: Major life-science tools company encompassing R&D Systems, Novus Biologicals, and Tocris, with extensive antibody and reagent catalogs covering histology, fibrosis, and ECM research. Comparable as a broad incumbent whose portfolio overlaps 3Helix's collagen/fibrosis research applications and which could credibly develop competing collagen-damage reagents.

Emerging players

  • FibroGen: Clinical-stage biopharmaceutical company developing therapeutics for fibrosis and connective tissue disorders. Comparable as an emerging player targeting the same fibrotic-disease indications (IPF, MASH) that 3Helix's bioACTIVE CHP platform is positioned to address therapeutically.

Direct peers

  • Biotium: Specialty reagent developer of fluorescent dyes, viability assays, and histology stains used in similar research workflows. Comparable as a similarly sized specialty reagent vendor selling fluorescent conjugates (analogous to 3Helix's F-CHP and R-CHP) into the same academic and pharma imaging markets.
  • Echelon Biosciences: Life science research reagent manufacturer focused on lipid signaling and related research tools, with a distribution footprint that overlaps 3Helix's US academic and pharma channels. Comparable as a similarly sized specialty reagent vendor targeting niche research applications.
  • CollPlant (formerly Collagen Solutions): Develops recombinant human collagen and bioengineered ECM products for research and medical applications. Comparable because it operates in the collagen-targeted regenerative and research market with overlapping customers in fibrosis and tissue-repair research.
  • Advanced BioMatrix: Specializes in collagen-based, ECM, and 3D tissue research reagents, including collagen hydrogels and scaffolds. Directly comparable because it serves the same collagen-research customer base with overlapping histology and tissue-engineering products, and is also a US distributor for 3Helix's CHP products.

Others

  • Nordic BioSite: Pan-European distributor of specialty life-science research reagents. Comparable as a channel peer that aggregates and distributes niche reagents (including collagen-related products) across European academic and biotech customers that 3Helix also serves via its regional distributor network.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

3Helix social profiles

Digital presence

3Helix financial estimates

Financial estimate

Revenue estimate

Valuation estimate

3Helix leadership team

Management profile

Number of profiles

Profiles3 records

3Helix funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

3Helix M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 3Helix

What does 3Helix do?

3Helix manufactures and sells Collagen Hybridizing Peptide (CHP) research reagents — short synthetic peptides that selectively bind denatured, damaged, or remodeling collagen via triple-helix reformation. The portfolio includes five labeled variants (F-CHP, B-CHP, R-CHP, In Vivo CHP, Auto-CHP) used by academic, pharmaceutical, and biotech researchers in histopathology, fibrosis, cancer, cardiovascular, and in vivo imaging studies. The company is also developing a bioACTIVE CHP platform that combines collagen-targeting with therapeutic payload delivery.

Is 3Helix a public or private company?

3Helix is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was 3Helix founded?

3Helix was founded in 2015. It employs 11 to 50 people.

Where is 3Helix based?

3Helix is headquartered in Salt Lake City, United States, in the North America region.

How does 3Helix make money?

One revenue line is on record: research Reagent Sales.

Who are 3Helix's main competitors?

Broad incumbents on record are Sigma-Aldrich (Merck KGaA Life Science), Abcam (Danaher), Cell Signaling Technology and Bio-Techne. FibroGen is listed as an emerging player. Direct peers are Biotium, Echelon Biosciences, CollPlant (formerly Collagen Solutions) and Advanced BioMatrix. Nordic BioSite is listed as an others.

Does 3Helix have an API?

No public API is recorded for 3Helix.

What industry is 3Helix in?

3Helix's product category is Life Science Research Reagents. Its primary akta.pro industry code is HLAAAAAH, Therapeutic Peptides & Protein/Peptide Biologics, with a secondary code of HLAAAIAC, Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals